Sign in

You're signed outSign in or to get full access.

Elizabeth Pitman

Director at MPW
Board

About Elizabeth N. Pitman

Independent director of Medical Properties Trust (MPW) since 2018; age 61. A healthcare lawyer with expertise in healthcare regulatory matters, privacy/data/cybersecurity compliance, technology licensing, and M&A; B.S. in Accounting (University of Alabama) and J.D. (University of Alabama School of Law). Serves as Chair of the Ethics, Nominating & Corporate Governance Committee and Chair of the Risk Committee; also member of Environmental & Social Responsibility Committee. Determined independent under NYSE standards; incumbent directors attended at least 75% of Board/committee meetings in 2024; all directors in office attended the 2024 annual meeting.

Past Roles

OrganizationRoleTenureCommittees/Impact
Success EHS, Inc.General CounselOct 2008–Jul 2013Legal leadership for EHR and revenue cycle provider; healthcare regulatory/compliance focus.
Vitera Healthcare Solutions, LLCCorporate CounselJul 2013–Dec 2013Counsel to healthcare IT provider; privacy/data security compliance.
Holland & Knight LLP (formerly Waller, Lansden, Dortch & Davis LLP)Attorney (Healthcare)2015–presentAdvises hospitals/health systems, surgery centers, physician groups, HIT companies on healthcare regulatory, privacy/cybersecurity, tech licensing, and M&A.

External Roles

OrganizationRoleTenureNotes
Holland & Knight LLPHealthcare Attorney2015–presentLeading provider of legal services to the healthcare industry. No other public company directorships disclosed.

Board Governance

  • Committee assignments:
    • Ethics, Nominating & Corporate Governance Committee: Chair.
    • Risk Committee: Chair.
    • Environmental & Social Responsibility Committee: Member.
  • Independence: Board determined Pitman (and 6 other nominees) are independent under NYSE standards.
  • Attendance and engagement:
    • 2024 meetings: Board (7), Audit (4), Ethics/Nominating (4), Compensation (5), Environmental & Social (1); Risk Committee did not meet in 2024 (covered in full Board). Each incumbent director attended at least 75% of Board/committee meetings; all directors in office attended the 2024 annual meeting.
  • Lead Independent Director: Michael G. Stewart. Executive sessions of independent directors held regularly.
  • Governance practices: Majority voting for uncontested elections, proxy access, unclassified Board, opt-out of MUTA, anti-hedging/anti-pledging, clawback policy, and mandatory director retirement age.

Fixed Compensation

ComponentAmount (USD)Detail
Annual cash retainer$115,000Standard non-employee director retainer (2024).
Committee chair fees$60,000$30,000 Ethics/Nominating Chair + $30,000 Risk Chair (2024).
Lead Independent premium$0Not applicable to Pitman.
Total fees earned (cash)$175,000As reported for 2024.

Additional: Directors reimbursed for reasonable Board/committee meeting expenses; Director Retirement Policy pays lump sum at retirement equal to final annual retainer/12 × years of service.

Performance Compensation

GrantGrant dateSharesFair value (USD)Vesting
Annual director RS grantMar 15, 202429,914$128,032Vests over 3 years in equal quarterly installments.
  • Outstanding equity awards as of Dec 31, 2024: Unvested stock 26,920 shares. Note: beneficial ownership table includes 23,161 unvested shares (different counting conventions).

Other Directorships & Interlocks

CompanyRoleNotes
None disclosedProxy does not disclose other public company boards for Pitman.
  • Consultant independence for director pay: Compensation Committee engaged independent consultant Gressle & McGinley; assessed as independent; also reviewed non-employee director pay.

Expertise & Qualifications

  • Healthcare legal/regulatory, privacy/data/cybersecurity compliance, technology licensing, and M&A for hospitals, healthcare systems, and HIT companies.
  • Board skills matrix shows legal/regulatory, risk management, REIT/real estate, health care industry, cyber; Pitman marked for Strategic Planning, Risk Management, REIT/Real Estate, Health Care, Investment, Legal/Regulatory, Cyber.
  • Education: B.S. Accounting; J.D. (University of Alabama).

Equity Ownership

MetricValue
Total beneficial ownership76,740 shares (includes 23,161 unvested restricted shares; 5,923 shares held in spouse’s name).
Ownership as % of shares outstandingLess than 1% (606,654,233 shares outstanding basis for officers/directors).
Outstanding unvested director RS (12/31/24)26,920 shares.
Stock ownership guidelinesNon-employee directors: 3× annual fee; Company reports compliance “Yes” for non-employee directors.
Hedging/pledgingProhibited by Insider Trading Policy.

Governance Assessment

  • Strengths:
    • Dual committee chair roles (Ethics/Nominating and Risk) indicate central involvement in board effectiveness, refreshment, and enterprise risk oversight; independence affirmed by Board.
    • Regular executive sessions and majority voting enhance accountability; robust governance policies (anti-hedging/pledging, clawbacks, proxy access) support investor alignment.
    • Director pay structure balanced with cash retainer plus time-based equity, and ownership guidelines promoting alignment; independent consultant involvement in director pay oversight.
  • Watch items / red flags:
    • Risk Committee did not meet in 2024 (risk oversight handled in full Board); as Risk Chair, ensuring formal committee cadence resumption could bolster dedicated risk governance.
    • Related person transactions disclosed for other insiders (family employment; Johnson Healthcare Real Estate payments linked to an Aldag family member at vendor); no related party disclosures implicating Pitman in 2024, but continued monitoring advisable.
  • Independence & attendance: Independent under NYSE rules; incumbents met ≥75% attendance thresholds; annual meeting attendance strong.

Overall, Pitman’s healthcare regulatory and cybersecurity legal background aligns with MPW’s risk profile (tenant health, privacy/cyber, regulatory), and her leadership of Ethics/Nominating and Risk committees positions her as a key governance steward. Formalizing Risk Committee meeting activity and continued transparency on related-party reviews maintain investor confidence.